AU2001296547A1 - Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies - Google Patents
Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodiesInfo
- Publication number
- AU2001296547A1 AU2001296547A1 AU2001296547A AU9654701A AU2001296547A1 AU 2001296547 A1 AU2001296547 A1 AU 2001296547A1 AU 2001296547 A AU2001296547 A AU 2001296547A AU 9654701 A AU9654701 A AU 9654701A AU 2001296547 A1 AU2001296547 A1 AU 2001296547A1
- Authority
- AU
- Australia
- Prior art keywords
- antigen
- antibody
- cell
- methods
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Abstract
Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23755600P | 2000-10-02 | 2000-10-02 | |
US60/237,556 | 2000-10-02 | ||
PCT/US2001/030963 WO2002028481A2 (en) | 2000-10-02 | 2001-10-02 | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001296547A1 true AU2001296547A1 (en) | 2002-04-15 |
Family
ID=22894238
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001296507A Abandoned AU2001296507A1 (en) | 2000-10-02 | 2001-10-02 | Human anti-cd40 antibodies |
AU2001296545A Abandoned AU2001296545A1 (en) | 2000-10-02 | 2001-10-02 | Methods of therapy for b-cell malignancies |
AU2002211366A Abandoned AU2002211366A1 (en) | 2000-10-02 | 2001-10-02 | Human anti-cd40 antibodies |
AU2001296547A Abandoned AU2001296547A1 (en) | 2000-10-02 | 2001-10-02 | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001296507A Abandoned AU2001296507A1 (en) | 2000-10-02 | 2001-10-02 | Human anti-cd40 antibodies |
AU2001296545A Abandoned AU2001296545A1 (en) | 2000-10-02 | 2001-10-02 | Methods of therapy for b-cell malignancies |
AU2002211366A Abandoned AU2002211366A1 (en) | 2000-10-02 | 2001-10-02 | Human anti-cd40 antibodies |
Country Status (10)
Country | Link |
---|---|
US (5) | US7288252B2 (en) |
EP (3) | EP1326896B1 (en) |
JP (6) | JP4202127B2 (en) |
AT (3) | ATE327004T1 (en) |
AU (4) | AU2001296507A1 (en) |
CA (2) | CA2424296A1 (en) |
DE (2) | DE60119945T2 (en) |
ES (1) | ES2357051T3 (en) |
PT (1) | PT1326896E (en) |
WO (4) | WO2002028481A2 (en) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
WO2002028481A2 (en) * | 2000-10-02 | 2002-04-11 | Chiron Corporation | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
US7906492B2 (en) | 2001-01-16 | 2011-03-15 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
US7507724B2 (en) * | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
ATE374214T1 (en) | 2001-04-27 | 2007-10-15 | Kirin Brewery | MONOCLONAL ANTI-CD-40 ANTIBODY |
EP1684869B1 (en) | 2003-11-04 | 2011-07-20 | Novartis Vaccines and Diagnostics, Inc. | Methods of therapy for b cell-related cancers |
US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
CN1929862B (en) * | 2003-11-04 | 2012-02-15 | 诺华疫苗和诊断公司 | Use of antagonist anti-CD40 antibodies for treatment of chronic lymphocytic leukemia |
DE602004028643D1 (en) * | 2003-11-04 | 2010-09-23 | Novartis Vaccines & Diagnostic | METHOD FOR TREATING SOLID TUMORS EXPRESSING CD40 CELL SURFACE ANTIGEN |
ATE474599T1 (en) | 2003-11-04 | 2010-08-15 | Novartis Vaccines & Diagnostic | USE OF ANTAGONIST ANTI-CD40 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF MULTIPLE MYELOMA |
SI1682180T1 (en) * | 2003-11-04 | 2010-03-31 | Novartis Vaccines & Diagnostic | Antagonist anti-cd40 monoclonal antibodies and methods for their use |
US20050136055A1 (en) * | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
US20070292439A1 (en) * | 2004-04-27 | 2007-12-20 | Novartis Vaccines And Diagnostics, Inc. | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
WO2006109045A2 (en) | 2005-04-09 | 2006-10-19 | Fusion Antibodies Limited | Cathepsin s antibody |
AU2006247067B2 (en) * | 2005-05-18 | 2012-06-07 | Novartis Ag | Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling |
DK1889065T3 (en) * | 2005-05-18 | 2013-09-02 | Xoma Technology Ltd | METHODS OF DIAGNOSIS AND TREATMENT OF DISEASES WITH AN AUTO-IMMUNE AND / OR INFLAMMATION COMPONENT |
CN101325970B (en) * | 2005-11-01 | 2013-08-14 | 诺华有限公司 | Uses of anti-cd40 antibodies |
US20090053221A1 (en) * | 2006-01-17 | 2009-02-26 | Cheung Nai-Kong V | Immune response enhancing glucan |
US8323644B2 (en) * | 2006-01-17 | 2012-12-04 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
US8945564B2 (en) | 2006-04-21 | 2015-02-03 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions |
CN101479375B (en) | 2006-05-03 | 2016-03-30 | 科罗拉多州立大学董事会 | CD40 agonist antibody/type 1 interferon synergistic adjuvant combines, comprise the purposes of aforesaid binding substances and the therapeutical agent as enhancing cellular immunization thereof |
US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
CA2693053C (en) * | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
RU2491095C2 (en) * | 2007-11-09 | 2013-08-27 | Новартис Аг | Using anti-cd40-antibodies |
US8551485B2 (en) | 2008-01-23 | 2013-10-08 | Xencor, Inc. | Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells |
US9562104B2 (en) | 2009-03-10 | 2017-02-07 | Baylor Research Institute | Anti-CD40 antibodies |
CA2754764A1 (en) | 2009-03-10 | 2010-09-16 | Baylor Research Institute | Antigen presenting cell targeted cancer vaccines |
EP3219732A1 (en) | 2009-03-10 | 2017-09-20 | Baylor Research Institute | Antigen presenting cell targeted cancer vaccines |
WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
AR083847A1 (en) | 2010-11-15 | 2013-03-27 | Novartis Ag | FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES |
WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
EP4338750A2 (en) | 2011-03-11 | 2024-03-20 | Beth Israel Deaconess Medical Center Inc. | Anti-cd40 antibodies and uses thereof |
AR085573A1 (en) | 2011-03-25 | 2013-10-09 | Baylor Res Inst | COMPOSITIONS AND IMMUNIZATION METHODS AGAINST THE VIRUS OF HEPATITIS C |
ES2664619T3 (en) * | 2011-04-21 | 2018-04-20 | Bristol-Myers Squibb Company | Antibody polypeptides that antagonize CD40 |
CN104105707B (en) | 2011-11-17 | 2020-03-06 | G·容 | Bispecific antibodies for medical use |
JP2016011258A (en) * | 2012-10-26 | 2016-01-21 | 株式会社ペルセウスプロテオミクス | Anti human cd40 monoclonal antibody and use thereof |
WO2014076292A1 (en) | 2012-11-19 | 2014-05-22 | Baliopharm Ag | Recombinant bispecific antibody binding to cd20 and cd95 |
CN106103483A (en) | 2014-01-13 | 2016-11-09 | 贝勒研究院 | The novel vaccine of the related disease of anti-HPV with HPV |
EP3113796A1 (en) | 2014-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
CN107073118B (en) | 2014-10-29 | 2022-03-01 | 西雅图基因公司 | Dosage and administration of non-fucosylated anti-CD 40 antibody |
CA2969847A1 (en) | 2014-12-10 | 2016-06-16 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
AU2016270640B2 (en) | 2015-05-29 | 2022-03-10 | Abbvie Inc. | Anti-CD40 antibodies and uses thereof |
AU2016315873B2 (en) | 2015-09-04 | 2022-08-18 | Primatope Therapeutics Inc. | Humanized anti-CD40 antibodies and uses thereof |
EP3355921A4 (en) * | 2015-09-30 | 2019-05-22 | Janssen Biotech, Inc. | Antagonistic antibodies specifically binding human cd40 and methods of use |
US11365256B2 (en) | 2016-06-08 | 2022-06-21 | Xencor, Inc. | Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases |
KR102531889B1 (en) | 2016-06-20 | 2023-05-17 | 키맵 리미티드 | Anti-PD-L1 and IL-2 cytokines |
BR112019000512A2 (en) | 2016-07-14 | 2019-04-24 | Genmab A/S | antibody, nucleic acid, expression vector, host cell, composition, methods of treating a disease, to produce a bispecific antibody and to detect if cross-linking between cd40 and cd137 expressing cells occurs in a sample, use of a multispecific antibody and kit |
EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
CA3054632A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
CA3064298A1 (en) | 2017-06-01 | 2018-12-06 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof |
CN108503708B (en) * | 2017-09-01 | 2021-07-30 | 北京智仁美博生物科技有限公司 | Anti-human CD47 antibodies and uses thereof |
US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
KR20210035805A (en) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | Increased immune activity through regulation of postcellular signaling factors |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
EP3860653A1 (en) | 2018-10-05 | 2021-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
CN116726362A (en) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | Methods and devices for treating diseases with biologic therapeutic agents |
CN112969714B (en) | 2018-11-30 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | anti-CD 40 antibodies, antigen binding fragments thereof and medical uses thereof |
EP3939998A4 (en) | 2018-11-30 | 2022-08-10 | Jiangsu Hengrui Medicine Co., Ltd. | Cd40 antibody pharmaceutical composition and use thereof |
AU2020216250A1 (en) * | 2019-02-01 | 2021-08-26 | LAVA Therapeutics N.V. | Novel CD40-binding antibodies |
NL2022494B1 (en) * | 2019-02-01 | 2020-08-19 | Lava Therapeutics B V | Novel CD40-binding antibodies |
WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
CN115666704A (en) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | Ingestible device for delivery of therapeutic agents to the gastrointestinal tract |
US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
WO2022006179A1 (en) | 2020-06-29 | 2022-01-06 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
CA3202891A1 (en) | 2021-01-28 | 2022-08-04 | Kara Olson | Compositions and methods for treating cytokine release syndrome |
AU2022233547A1 (en) | 2021-03-09 | 2023-09-28 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in therapy |
KR20230165276A (en) | 2021-03-31 | 2023-12-05 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | Thanotransmission polypeptides and their use in the treatment of cancer |
KR20240026507A (en) | 2021-06-29 | 2024-02-28 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | Immune cells engineered to promote thananotransmission and uses thereof |
WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
CN117500816A (en) | 2021-08-26 | 2024-02-02 | 映恩生物制药(苏州)有限公司 | Steroid and conjugate thereof |
WO2023198851A1 (en) | 2022-04-14 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US142358A (en) * | 1873-09-02 | Improvement in the purification of illuminating-gas | ||
US59427A (en) * | 1866-11-06 | Improvement in fences | ||
US4355023A (en) * | 1980-09-30 | 1982-10-19 | The Massachusetts General Hospital | Antibody fragment compositions and process |
NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
US4689299A (en) * | 1982-09-30 | 1987-08-25 | University Of Rochester | Human monoclonal antibodies against bacterial toxins |
EP0138854B1 (en) | 1983-03-08 | 1992-11-04 | Chiron Mimotopes Pty. Ltd. | Antigenically active amino acid sequences |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4727018A (en) * | 1984-05-18 | 1988-02-23 | Eichner Ronald D | Immunoregulation of transplantable tissue |
US5068223A (en) * | 1985-09-09 | 1991-11-26 | Board Of Regents, University Of Texas System | Hydrophobic peptide esters and amides |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5182368A (en) * | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
US4923872A (en) * | 1986-08-26 | 1990-05-08 | Warner-Lambert Co. | Analogues of pyrrolo[3,2d]pyrimidin-4-ones |
US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
ES2051726T3 (en) * | 1987-01-17 | 1994-07-01 | Asta Medica Ag | PROCEDURE FOR PREPARING INJECTABLE PRODUCTS CONTAINING AZELASTIN AND THEOFILINE OR AZELASTIN AND BETA-MIMETICS. |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5100899A (en) * | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
EP0434879A1 (en) | 1989-12-14 | 1991-07-03 | Schering-Plough | Method of making factor dependent human B cell lines |
JPH06508501A (en) | 1990-07-02 | 1994-09-29 | ブリストル―マイアーズ スクイブ カンパニー | Ligand for CD28 receptor on B cells and method for regulating cell-cell interaction using the ligand |
ATE274055T1 (en) | 1991-10-25 | 2004-09-15 | Immunex Corp | NEW CYTOKINE |
CA2103887C (en) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
CA2089229C (en) | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
US5684129A (en) | 1992-07-07 | 1997-11-04 | Fish; Eleanor N. | Interferon receptor binding peptides |
US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
EP0945465B1 (en) * | 1992-07-09 | 2006-09-13 | Novartis Vaccines and Diagnostics, Inc. | Antagonistic monoclonal antibodies to human CD40 |
AU5098493A (en) | 1992-08-21 | 1994-03-15 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
DE614989T1 (en) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Method for in vivo selection of ligand binding proteins. |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
NZ273504A (en) | 1993-10-01 | 1997-12-19 | Immunex Corp | Monoclonal antibodies (moabs) that specifically bind human cd40 molecules and cd40 ligand binding |
DE69433820T2 (en) | 1993-12-23 | 2005-06-23 | Immunex Corp., Seattle | USE OF SOLUBLE OLIGOMERIC CD40 LIGANDS OR MONOCLONAL ANTIBODIES FOR THE MANUFACTURE OF A MEDICINE FOR PREVENTING OR TREATING NEOPLASTIC DISEASES |
EP0823941A4 (en) * | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
CA2369820A1 (en) | 1999-04-16 | 2000-10-26 | Frank Dicker | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
AU1072701A (en) | 1999-10-04 | 2001-05-10 | Chiron Corporation | Cd40 antagonist for treating psoriasis |
US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
WO2001034649A2 (en) | 1999-11-09 | 2001-05-17 | Chiron Corporation | Compositions and methods for treating autoimmune diseases and transplant rejections |
US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
AU2001259215A1 (en) * | 2000-04-28 | 2001-11-12 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
WO2002028481A2 (en) * | 2000-10-02 | 2002-04-11 | Chiron Corporation | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
-
2001
- 2001-10-02 WO PCT/US2001/030963 patent/WO2002028481A2/en active IP Right Grant
- 2001-10-02 AU AU2001296507A patent/AU2001296507A1/en not_active Abandoned
- 2001-10-02 EP EP01979395A patent/EP1326896B1/en not_active Expired - Lifetime
- 2001-10-02 AT AT01977428T patent/ATE327004T1/en not_active IP Right Cessation
- 2001-10-02 EP EP01977428A patent/EP1322383B9/en not_active Expired - Lifetime
- 2001-10-02 AU AU2001296545A patent/AU2001296545A1/en not_active Abandoned
- 2001-10-02 DE DE60119945T patent/DE60119945T2/en not_active Expired - Lifetime
- 2001-10-02 JP JP2002532304A patent/JP4202127B2/en not_active Expired - Fee Related
- 2001-10-02 US US10/380,223 patent/US7288252B2/en not_active Expired - Fee Related
- 2001-10-02 AT AT01979395T patent/ATE489403T1/en active
- 2001-10-02 PT PT01979395T patent/PT1326896E/en unknown
- 2001-10-02 AU AU2002211366A patent/AU2002211366A1/en not_active Abandoned
- 2001-10-02 JP JP2002532486A patent/JP4271440B2/en not_active Expired - Lifetime
- 2001-10-02 WO PCT/US2001/030859 patent/WO2002028905A2/en active Application Filing
- 2001-10-02 DE DE60143535T patent/DE60143535D1/en not_active Expired - Lifetime
- 2001-10-02 ES ES01979395T patent/ES2357051T3/en not_active Expired - Lifetime
- 2001-10-02 AT AT06005656T patent/ATE541860T1/en active
- 2001-10-02 AU AU2001296547A patent/AU2001296547A1/en not_active Abandoned
- 2001-10-02 CA CA002424296A patent/CA2424296A1/en not_active Abandoned
- 2001-10-02 WO PCT/US2001/030961 patent/WO2002028480A2/en active Application Filing
- 2001-10-02 WO PCT/US2001/030857 patent/WO2002028904A2/en active Application Filing
- 2001-10-02 CA CA002424749A patent/CA2424749A1/en not_active Abandoned
- 2001-10-02 EP EP06005656A patent/EP1717251B1/en not_active Expired - Lifetime
-
2007
- 2007-08-31 US US11/849,107 patent/US7445780B2/en not_active Expired - Fee Related
- 2007-11-19 JP JP2007299859A patent/JP2008156339A/en active Pending
- 2007-11-26 JP JP2007305086A patent/JP2008074870A/en active Pending
-
2008
- 2008-08-28 JP JP2008220544A patent/JP4838831B2/en not_active Expired - Fee Related
- 2008-10-06 US US12/246,029 patent/US7611708B2/en not_active Expired - Fee Related
-
2009
- 2009-06-16 JP JP2009143746A patent/JP2009201523A/en active Pending
- 2009-09-28 US US12/568,373 patent/US7820170B2/en not_active Expired - Fee Related
-
2010
- 2010-09-27 US US12/891,415 patent/US8088383B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001296547A1 (en) | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies | |
EP1684805B8 (en) | Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma | |
WO2005044854A3 (en) | Antagonist anti-cd40 monoclonal antibodies and methods for their use | |
WO2005044304A3 (en) | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia | |
AU2190997A (en) | Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation | |
HK1093690A1 (en) | Methods of therapy for solid tumors expressing the cd40 cell-surface antigen | |
HK1106736A1 (en) | Combination therapy comprising anti-cd20 and anti-cd40 antibodies for the treatment of b cell-related cancers | |
NZ515992A (en) | Use of antibodies against CD20 for the treatment of the graft versus host disease | |
NZ515464A (en) | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains | |
NZ596878A (en) | Methods of administering anti-tnfalpha antibodies | |
AU3386100A (en) | Anti-tnfalpha antibodies in therapy of asthma | |
TR200103432T2 (en) | Blocking monoclonal VLA-1 antibody and its use in the treatment of inflammatory diseases. | |
WO2004019886A3 (en) | Methods for up-regulating antigen expression in tumors | |
EP2641611A3 (en) | Combination therapy | |
RU2002103808A (en) | METHOD FOR TREATING PAIN SYNDROME IN ONCOLOGIC PATIENTS | |
WO2004019991A3 (en) | Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma | |
NZ329403A (en) | Treatment of B-cell lymphomas using a CD40 binding protein that inhibits the binding of CD40 to CD40L | |
CY1114654T1 (en) | ANTI-CD40 MONOCLONIC ANTIBODIES ANTI-COMPONENTS AND METHODS FOR USE |